National Research (NASDAQ:NRC) Stock Passes Above 200 Day Moving Average of $48.50

National Research Co. (NASDAQ:NRC) shares passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $48.50 and traded as high as $64.22. National Research shares last traded at $63.79, with a volume of 6,875 shares.

Separately, ValuEngine downgraded shares of National Research from a “buy” rating to a “hold” rating in a report on Wednesday, October 2nd.

The company’s fifty day simple moving average is $61.21 and its 200 day simple moving average is $48.86. The company has a current ratio of 0.69, a quick ratio of 0.69 and a debt-to-equity ratio of 1.07. The stock has a market capitalization of $1.59 billion, a P/E ratio of 52.33 and a beta of 0.79.

National Research (NASDAQ:NRC) last announced its quarterly earnings results on Tuesday, November 5th. The company reported $0.31 EPS for the quarter. National Research had a net margin of 25.01% and a return on equity of 130.25%. The firm had revenue of $32.47 million during the quarter.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Tuesday, December 31st will be issued a $0.21 dividend. This represents a $0.84 annualized dividend and a yield of 1.31%. This is an increase from National Research’s previous quarterly dividend of $0.19. The ex-dividend date of this dividend is Monday, December 30th.

In other National Research news, major shareholder Amandla Mk Trust sold 500,000 shares of the firm’s stock in a transaction on Wednesday, September 18th. The shares were sold at an average price of $60.50, for a total value of $30,250,000.00. Also, Director Donald M. Berwick sold 6,989 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $62.04, for a total transaction of $433,597.56. Over the last three months, insiders sold 551,435 shares of company stock valued at $33,742,164. Insiders own 4.50% of the company’s stock.

Several institutional investors have recently bought and sold shares of NRC. Aperio Group LLC purchased a new stake in shares of National Research during the 2nd quarter valued at $176,000. Advisor Group Inc. raised its position in shares of National Research by 17.8% during the 2nd quarter. Advisor Group Inc. now owns 2,263 shares of the company’s stock valued at $131,000 after buying an additional 342 shares in the last quarter. Janus Henderson Group PLC purchased a new stake in shares of National Research during the 2nd quarter valued at $682,000. Swiss National Bank raised its position in shares of National Research by 13.8% during the 2nd quarter. Swiss National Bank now owns 23,100 shares of the company’s stock valued at $1,330,000 after buying an additional 2,800 shares in the last quarter. Finally, Conestoga Capital Advisors LLC raised its position in shares of National Research by 2.6% during the 2nd quarter. Conestoga Capital Advisors LLC now owns 626,878 shares of the company’s stock valued at $36,102,000 after buying an additional 15,789 shares in the last quarter. Hedge funds and other institutional investors own 39.67% of the company’s stock.

National Research Company Profile (NASDAQ:NRC)

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement.

Featured Story: Stock Portfolio Tracker

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.